Itamar Medical Launches Enhancements to WatchPAT™ Product Line at SLEEP 2021
June 07 2021 - 6:00AM
Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical
device and digital health company focused on the integration of
sleep apnea management into the cardiac patient care pathway, today
announced two enhancements to its WatchPAT™ product line that the
Company plans to unveil on June 11 during the Virtual SLEEP 2021
Conference, a joint meeting of the American Academy of Sleep
Medicine and the Sleep Research Society.
“These product enhancements reflect our commitment to continuous
improvement of the sleep patient pathway by leveraging Itamar’s
digital health platform to deliver increased home sleep testing
efficiency, broader information access beyond the Apnea Hypopnea
Index (AHI) and improving the quality of sleep clinics’ operations
around home sleep diagnostics,” said Gilad Glick, President and
Chief Executive Officer.
WatchPAT™ ONE with SleepPath™ For the first
time, subjective data can be collected from patients through the
WatchPAT smartphone app, both before and after the home sleep test.
This new service, WatchPAT™ with SleePath™, will be offered to
sleep clinics and will be customizable based on the specific needs
of the sleep clinic and their patients. This new service gives
sleep health providers simple and easy access to digital
documentation in one report that combines sleep study metrics and
patient self-reported data, replacing traditional paper
documentation.
WatchPAT™ONE-M The WatchPAT™ONE-M, an
enhancement to the Company’s innovative WatchPAT™ONE, enables sleep
physicians to order multi-night test and follow-up with their
patients after each night of testing to determine if further
testing would be beneficial. This is most relevant in
situations where the need for further evaluation become apparent
after the first night of testing or if new information provided by
the patient raises concerns and additional testing could be
critical.
“As our WatchPAT™ technology becomes increasingly more
predominant in sleep disorder diagnostics, we look forward to
leveraging our growing customer base to transition our WatchPAT™
app into an active communication tool for patients and their
physicians. The addition of WatchPAT™ ONE-M is expected to support
a higher level of interaction between sleep physicians and their
patients, as it provides an opportunity to leverage patient
feedback in parallel with the sleep test, deliver one comprehensive
report, and enable physicians to follow-up with their patients more
effectively,” added Glick.
“We are excited with the announcement of WatchPAT™ with
SleePath™ and WatchPAT™ONE-M multi-night capability. These
advancements will further simplify the sleep diagnosis process and
are a critical step towards more personalized sleep diagnostics as
so many things impact sleep, and not all nights are the same,” said
Dr. Matthew Schmitt, Clinical Governance Council Chief of Sleep
Medicine, Piedmont Healthcare.
About Itamar Medical Ltd.Itamar Medical is a
medical technology company focused on the development and
commercialization of non-invasive medical devices and solutions to
aid in the diagnosis of respiratory sleep disorders. Itamar Medical
commercializes a digital healthcare platform to facilitate the
continuum of care for effective sleep apnea management with a focus
on the core sleep, cardiology and direct to consumer markets.
Itamar Medical offers a Total Sleep Solution to help physicians
provide comprehensive sleep apnea management in a variety of
clinical environments to optimize patient care and reduce
healthcare system costs. The Company’s key product, WatchPAT, is
commercially available within major markets including the US,
Japan, and Europe. Itamar Medical is a public company traded on the
Nasdaq and on the Tel Aviv Stock Exchanges, and is based in
Caesarea, Israel with U.S. headquarters based in Atlanta, GA. For
additional information visit www.itamar-medical.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and other applicable securities laws. Statements preceded
by, followed by, or that otherwise include the words "believes",
"expects", "anticipates", "intends", "estimates", "plans", and
similar expressions or future or conditional verbs such as "will",
"should", "would", "may" and "could" are generally forward-looking
in nature and not historical facts. For example, when we discuss
our WatchPAT™ technology becoming increasingly more predominant in
sleep disorder diagnostics we are using forward looking statements.
Because such statements deal with future events, they are subject
to various risks, uncertainties and assumptions, including events
and circumstances out of Itamar Medical's control and actual
results, expressed or implied by such forward-looking statements,
could differ materially from Itamar Medical's current expectations.
Factors that could cause or contribute to such differences include,
but are not limited to, risks, uncertainties and assumptions
discussed from time to time by us in reports filed with, or
furnished to, the U.S. Securities and Exchange Commission (“SEC”)
and the Israel Securities Authority (“ISA”), including our latest
Annual Report on Form 20-F which is on file with the SEC and the
ISA. Except as otherwise required by law, we undertake no
obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events.
Itamar Medical Investor Relations Contact
(U.S.)
Leigh Salvo Gilmartin GroupPhone:
+1-510-693-5238investors@itamar-medical.com
Itamar Medical (NASDAQ:ITMR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Itamar Medical (NASDAQ:ITMR)
Historical Stock Chart
From Sep 2023 to Sep 2024